GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway
Drug Design, Development and Therapy · 2026
DOI: 10.2147/dddt.s585989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Yunsheng Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, People's Republic of China. Hauptthemen laut MEDLINE: Doxorubicin, Sodium-Hydrogen Exchanger 1, Cardiotoxicity, Guanidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, People's Republic of China.
- Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, People's Republic of China.
- College of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
ORCID-Profile: Yunsheng Xu, Yanan Li, Zhiling Cheng, Chenyue Shao, Xinru Zhao, Yuming Liu, Xiangbo Gou, Congxin Li
Zitieren
APA
Xu, Y., Li, Y., Cheng, Z., Shao, C., Zhao, X., Liu, Y., Gou, X., & Li, C. (2026). GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s585989
Vancouver
Xu Y, Li Y, Cheng Z, Shao C, Zhao X, Liu Y, et al. GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s585989
BibTeX
@article{Xu2026,
author = {Xu, Yunsheng and Li, Yanan and Cheng, Zhiling and Shao, Chenyue and Zhao, Xinru and Liu, Yuming and Gou, Xiangbo and Li, Congxin},
title = {GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway},
journal = {Drug Design, Development and Therapy},
year = {2026},
doi = {10.2147/dddt.s585989}
}
EUVIMED